<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28954393</article-id>
<article-id pub-id-type="pmc">5666738</article-id>
<article-id pub-id-type="doi">10.3390/ijms18102056</article-id>
<article-id pub-id-type="publisher-id">ijms-18-02056</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Riikonen</surname>
<given-names>Raili</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-ijms-18-02056">Child Neurology, Children’s Hospital, University of Eastern Finland and Kuopio University Hospital, P.O. Box 1627, FI-70211 Kuopio, Finland; <email>raili.riikonen@kolumbus.fi</email>; Tel.: +358-50-5174696; Fax: +358-19-668418</aff>
<pub-date pub-type="epub">
<day>26</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>10</month>
<year>2017</year>
</pub-date>
<volume>18</volume>
<issue>10</issue>
<elocation-id>2056</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 by the author.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Insulin-like growth factors play a key role for neuronal growth, differentiation, the survival of neurons and synaptic formation. The action of IGF-1 is most pronounced in the developing brain. In this paper we will try to give an answer to the following questions: Why are studies in children important? What clinical studies in neonatal asphyxia, infantile spasms, progressive encephalopathy–hypsarrhythmia–optical atrophy (PEHO) syndrome, infantile ceroid lipofuscinosis (INCL), autistic spectrum disorders (ASD) and subacute sclerosing encephalopathy (SSPE) have been carried out? What are IGF-based therapeutic strategies? What are the therapeutic approaches? We conclude that there are now great hopes for the therapeutic use of IGF-1 for some neurological disorders (particularly ASD).</p>
</abstract>
<kwd-group>
<kwd>insulin-like growth factor</kwd>
<kwd>pathogenesis</kwd>
<kwd>neonates</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>neurodegeneration</kwd>
<kwd>neuroprotection</kwd>
<kwd>children</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-18-02056">
<title>1. Introduction</title>
<p>The members of the insulin gene family (insulin-like growth factors 1 and 2; (IGF-1 and IGF-2, respectively) play a key trophic role in the central nervous system (CNS). Of the two, IGF-1 is more important. In fact, IGF-1 stimulates DNA synthesis, cell production, neurite outgrowth, enhances secretion of several neurotransmitters, and mediates the action of other neurotrophic factors (particularly brain derived neurotrophic factor (BDNF)).</p>
<p>Therefore, foetal brain growth is extremely sensitive to IGF-1 levels. Mice lacking IGF-1 or IGF-1 receptors have decreased brain volumes [<xref ref-type="bibr" rid="B1-ijms-18-02056">1</xref>], whereas IGF-2 over-expression increases brain growth [<xref ref-type="bibr" rid="B2-ijms-18-02056">2</xref>]. However, CNS sensitivity to IGF-1 is not the same among the different CNS regions. In fact, while cerebellar Purkinje cells and granule cells, oligodendrocytes, and motor-neurons are particularly sensitive to IGF-1 deficiency, other cells are independent of the presence of IGF-1 [<xref ref-type="bibr" rid="B3-ijms-18-02056">3</xref>]. IGF-1 and its receptors are found widely distributed in all brain regions. In vitro studies examining the effect of IGF-1 in neural stem cells report increased neural progenitor cell proliferation and maintenance in cell cultures following treatment with IGF-1. IGF-1 increases myelination by increasing the number of myelinated axons and the thickness of myelin sheaths; moreover, IGF-1 increases both the number of oligodendrocytes and the amount of axonal myelin produced. IGF-1 increases oligodendrocyte numbers by acting as a mitogen and inhibiting apoptosis. Both neurons and glial cells have been observed to express IGF-1 mRNA, which leads to immature glial precursors developing into oligodendrocytes [<xref ref-type="bibr" rid="B4-ijms-18-02056">4</xref>]. Oligodendrocytes mediate the myelinations of axons and constitute the vast majority of cells in the white matter. Consequently, a low production of IGF-1 may be related to the degeneration of myelin [<xref ref-type="bibr" rid="B5-ijms-18-02056">5</xref>].</p>
</sec>
<sec id="sec2-ijms-18-02056">
<title>2. Why Studies in Children with IGF-1 Are Important?</title>
<p>Neurotrophic factors play a particularly important role in the developing brain. There is a dramatic growth and maturation of the brain and its different trajectories [<xref ref-type="bibr" rid="B6-ijms-18-02056">6</xref>]. This dynamic neurodevelopment continues from the embryonic period to adolescence with significant changes in myelination, synaptogenesis and neurotransmitter distribution throughout the maturation phase. Since the development of the fetal brain requires the organized sequential expression of genes during critical periods, the fetal brain is very sensitive to insults occurring during its development. However, the developing brain also possesses a superior capacity to reorganize after insults. This is considered to be due to increased receptor sensitivity to large amounts of neurotrophic factors acting in this period of life and in early childhood [<xref ref-type="bibr" rid="B7-ijms-18-02056">7</xref>]. Therefore, brain plasticity is greater in infants than in adults, this is the reason why it would be important to carry out therapeutic trials with neurotrophic factors such as IGF-1 in children suffering damages, commencing as soon as possible once the damage has occurred.</p>
</sec>
<sec id="sec3-ijms-18-02056">
<title>3. What Clinical Studies Have Been Carried Out?</title>
<sec id="sec3dot1-ijms-18-02056">
<title>3.1. Neonatal Asphyxia</title>
<p>Recombinant IGF-1 (rhIGF-1) is effective (neuroprotective) and non-toxic when administered 2 h after an induced hypoxic event in an animal model [<xref ref-type="bibr" rid="B8-ijms-18-02056">8</xref>]. In fetuses as well as in older children, hypoxia reduces circulating IGF-1 [<xref ref-type="bibr" rid="B9-ijms-18-02056">9</xref>,<xref ref-type="bibr" rid="B10-ijms-18-02056">10</xref>]. Critical illnesses reduce circulating IGF-1 concentrations after birth. Furthermore, preterm infants have already low serum concentrations of IGF-1, and episodes of hypoxia are a frequent finding in them during the first weeks of life [<xref ref-type="bibr" rid="B11-ijms-18-02056">11</xref>]. Preterm delivery may be precipitated by infection leading to the detection of markers of inflammation in cord blood samples, associated with reduced IGF-1 concentrations [<xref ref-type="bibr" rid="B12-ijms-18-02056">12</xref>,<xref ref-type="bibr" rid="B13-ijms-18-02056">13</xref>]. Acute and chronic hypoxia and inflammation also increase the concentrations of IGF-binding protein-1 (IGFBP-1). Hence the amount of free IGF-1 is lower because of its binding to IGFBP-1, and this correlates with the poor brain development observed in preterm infants [<xref ref-type="bibr" rid="B12-ijms-18-02056">12</xref>,<xref ref-type="bibr" rid="B14-ijms-18-02056">14</xref>]. With the development of magnetic resonance imaging (MRI), the impact of preterm birth on the different brain structures can be easily seen [<xref ref-type="bibr" rid="B15-ijms-18-02056">15</xref>].</p>
<p>Moreover, postnatal head circumference correlates positively with serum IGF-1 concentrations in preterm infants [<xref ref-type="bibr" rid="B16-ijms-18-02056">16</xref>]. Apart of these effects on the brain, IGF-1 treatment has both short-term and long-term potential benefits in many organ and systems of preterms: pulmonary and cardiovascular systems, and somatic growth [<xref ref-type="bibr" rid="B14-ijms-18-02056">14</xref>]. Clinical trials are required to determine the risks and benefits of IGF-1 replacement in very preterm infants, and in other newborns after ischemic brain injury. An ongoing phase II trial is trying determine the safety, feasibility and potential benefits and risks of IGF-1 replacement with IGF-1/IGFBP-3 in extremely premature infants.</p>
<p>In our study in human newborns suffering from severe neonatal asphyxia we did not analyse cerebrospinal fluid (CSF) IGF-1, but CSF BDNF was increased and β-nerve growth factor (NGF) decreased [<xref ref-type="bibr" rid="B17-ijms-18-02056">17</xref>,<xref ref-type="bibr" rid="B18-ijms-18-02056">18</xref>]. Increased BDNF concentrations might counteract neuronal damage. In turn, CSF NGF concentrations might serve as a marker of asphyxia.</p>
</sec>
<sec id="sec3dot2-ijms-18-02056">
<title>3.2. The Finnish Study: Infantile Spasms, PEHO Syndrome, INCL Autistic Spectrum Disorder (ASD): Infantile Autism and Rett Syndrome</title>
<p>CSF concentrations of nerve growth factors are thought to reflect concentrations in the brain more accurately than serum levels. The majority of the research studies published in this area are from our group’s work in Finland, hence they make up most of the studies reviewed. CSF IGF-1 from frozen (−70 °C) samples was measured in all these studies by radioimmunoassay with commercially available kits (Mediagnost<sup>®</sup>, Tubingen, Germany), according to the instructions of the manufacturer. The sensitivity of the assay was 0.02 µg/L. The CSF studies were taken as part of the diagnostic evaluation both for the patients and the age-matched controls. We included only control patients who had no conditions such as malnutrition, hepatic failure, chronic inflammation, diabetes or hypothyroidism which might have influenced the CSF concentrations of IGF-1. In addition to these controls with some minor neurological diseases we also used the results of “healthy” controls. These healthy controls were 16 age-matched children admitted to Kuopio University Hospital for surgery on the lower part of the body, to be performed under spinal anesthesia: herniotomy, urethral cystoscopy, knee arthroscopy, circumcision, and suture of traumatic wounds.</p>
<p>In that study we aimed to investigate the pathogenesis of some neurological disorders leading to mental retardation, both in acute and chronic diseases by examining different nerve growth factors in serum and CSF. The following neuropediatric diseases were studied: infantile spasms, INCL, PEHO, infantile autism and Rett syndrome (RTT). </p>
<p>The study adhered to the tenets of the Helsinki Declaration. The Ethics Committee of the Children’s Hospital, Helsinki, and Kuopio University Hospital, Kuopio, Finland, approved the study. The study had institutional approval. Patients or their caregivers gave informed consent to the research and to publishing the results obtained.</p>
<sec id="sec3dot2dot1-ijms-18-02056">
<title>3.2.1. Infantile Spasms </title>
<p>West syndrome (infantile spasms, IS) is a rare epileptic disorder with onset usually prior to the age of two years. Infantile spasms are characterized by clusters of infantile spasms with hypsarhythmia or modified hypsarrhythma on interictal electroencephalogram (EEG). It is an epileptic encephalopathy where cognitive, motor and sensory functions are altered by the epilepsy itself. The syndrome is classified into symptomatic (80%), cryptogenic (15–20%) and idiopathic (15%) groups. depending on the known etiology. The newer classification divides IS into structural-metabolic, infectious immune, genetic, and unknown groups [<xref ref-type="bibr" rid="B19-ijms-18-02056">19</xref>].</p>
<p>The mechanism of infantile spasms is currently unknown, and the molecular mechanisms that lead to the long-term consequences of infantile spasms are poorly understood. Many critical questions remain, e.g., what causes mental retardation in most patients. A specific period of brain maturation is believed to be fundamental to development of IS, although there might be discrepancies between brain development and age.</p>
<p>It has been suggested that early stress (injury or insult) during a critical pre-, peri-, and postnatal period of high corticotrophin-releasing hormone (CRF) abundance may increase CRF synthesis and activity. [<xref ref-type="bibr" rid="B20-ijms-18-02056">20</xref>]. CRF causes seizures during early brain development but not later. Although CRF acutely stimulates adrenocorticotrophic (ACTH) secretion, chronically elevated brain CRF desensitizes the CRF receptor and eventually decrease ACTH release [<xref ref-type="bibr" rid="B21-ijms-18-02056">21</xref>]. </p>
<p>An early brain-damaging insult (i.e., hypoxia, stroke, infection) may trigger a cascade of molecular and cellular changes. The epileptic process is considered to consist of three phases: initial insult, latency period (epileptogenesis), and recurrent seizures [<xref ref-type="bibr" rid="B22-ijms-18-02056">22</xref>].</p>
<p>In symptomatic (structural) infantile spasms the spasms may have their onset several months following a pre-, peri- or immediate post-natal brain injury. This latent period presents an opportunity for therapeutic intervention.</p>
<p>Steroids (immunosuppressive agents) are the first-line drugs for IS. The therapeutic action of ACTH in this disorder is unknown, but it might work by downregulating the secretion of CRF and other stress hormones.</p>
<p>IGFs influence the entire process of neurogenesis. As described above, brain growth is extremely sensitive to levels of IGF-1. IGF-1 also reduces neuro-inflammation [<xref ref-type="bibr" rid="B23-ijms-18-02056">23</xref>]. ACTH, glucocorticoids and a ketogenic diet can be effective therapies for infantile spasms and they all affect IGF-1 levels [<xref ref-type="bibr" rid="B24-ijms-18-02056">24</xref>,<xref ref-type="bibr" rid="B25-ijms-18-02056">25</xref>,<xref ref-type="bibr" rid="B26-ijms-18-02056">26</xref>].</p>
<p>In our study, children with symptomatic IS had markedly low CSF IGF-1 concentrations, and significantly lower ACTH concentrations when compared with children who had an idiopathic etiology. Symptomatic IS were characterized by a history of pre, peri- or postnatal damage. Prenatal stress has in animals been shown to decrease IGF-1 [<xref ref-type="bibr" rid="B27-ijms-18-02056">27</xref>]. In patients with infantile spasms, low CSF IGF-1 correlated with the severity and length of stress, cortical damage, poor response to therapy and poor cognition. The following hypothesis was postulated: “The brain cannot produce steroids, which stimulate secretion of IGF-1, an essential growth factor for survival of synapses high-lighting its potential use as a biomarker for disease severity. Patients with low CSF IGF-1 do not respond to therapy and there is an association between low IGF-1 levels and later worsening of mental retardation” [<xref ref-type="bibr" rid="B26-ijms-18-02056">26</xref>] (p. 1289). An association has also been found between the decline of brain growth and poor response to ACTH [<xref ref-type="bibr" rid="B28-ijms-18-02056">28</xref>], and, furthermore, an association between symptomatic infantile spasms and infantile autism [<xref ref-type="bibr" rid="B29-ijms-18-02056">29</xref>] (both conditions having low CSF IGF-1, see later).</p>
<p>In patients with symptomatic infantile spasms, the normalisation of IGF-1 axis, directly or indirectly, may contribute to normal development. We have no information about how IGF-1 administration would affect epilepsy in children. IGF-1 activation can be beneficial or harmful depending on the stage of the disease when using the hippocampal culture model of post-traumatic epileptogenesis [<xref ref-type="bibr" rid="B30-ijms-18-02056">30</xref>] However, in an animal model, treatment with IGF-I decreased seizure severity, increased hippocampal neurogenesis, and protected against neurodegeneration and was considered to be a possible potential treatment in temporal lobe epilepsy [<xref ref-type="bibr" rid="B31-ijms-18-02056">31</xref>].</p>
<p>In summary, in infantile spasms CSF concentrations of IGF-1 at the time of presentation seems to be a biomarker of (1) treatment response and progression of epilepsy, and (2) later cognitive outcome.</p>
</sec>
<sec id="sec3dot2dot2-ijms-18-02056">
<title>3.2.2. PEHO Syndrome</title>
<p>PEHO syndrome is a specific type of West syndrome that is characterized by progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO). Riikonen published a paper on nine families with infantile spasms in siblings [<xref ref-type="bibr" rid="B32-ijms-18-02056">32</xref>]. The medical history of the patients in five (11 siblings) of these families were compatible with PEHO syndrome. Salonen et al. [<xref ref-type="bibr" rid="B33-ijms-18-02056">33</xref>] described 14 patients from 11 families who had a progressive encephalopathy with early onset and called it PEHO syndrome. Somer presented diagnostic criteria for PEHO syndrome based on 14 PEHO syndrome families (19 patients) in her thesis [<xref ref-type="bibr" rid="B34-ijms-18-02056">34</xref>]. PEHO syndrome is an early childhood, autosomal recessive developmental and epileptic encephalopathy. It is characterised by severe cerebellar atrophy as a result of an almost complete loss of granule cells. Microcephaly develops at 12 months. Somer (1993) indicated that cerebellar hypoplasia is a cardinal diagnostic feature of PEHO syndrome. Head circumference was normal at birth, but usually dropped to 2 SD below average during the first year of life. <italic>ZNHIT3</italic> was very recently shown to be defective in PEHO syndrome [<xref ref-type="bibr" rid="B35-ijms-18-02056">35</xref>]. Through homozygosity mapping in Finnish families positional candidate genes were identified at the chromosome 17q17 locus in PEHO syndrome. Sanger sequencing techniques identified a homozygous missense variant, L31 &gt; S, in the <italic>ZNHIT3</italic> gene (OMIM 604500) as the primary genetic cause of PEHO syndrome [<xref ref-type="bibr" rid="B35-ijms-18-02056">35</xref>]. We studied IGF-1, nitrite, nitrate and nitric oxide, from the CSF of patients with an average age of five years. As indicated above, IGF-1 is very important for cerebellar neurons. Our results showed that the levels of IGF-1 in patients with PEHO syndrome were significantly lower than in age-matched controls [<xref ref-type="bibr" rid="B36-ijms-18-02056">36</xref>]. The only biochemical anomalies identified so far were elevated levels of nitrate and nitrite [<xref ref-type="bibr" rid="B37-ijms-18-02056">37</xref>] and low levels of insulin-like growth factor 1 (IGF-1) in CSF [<xref ref-type="bibr" rid="B36-ijms-18-02056">36</xref>,<xref ref-type="bibr" rid="B38-ijms-18-02056">38</xref>], and low high-density cholesterol in serum [<xref ref-type="bibr" rid="B39-ijms-18-02056">39</xref>].</p>
<p>The other half of Somer's original patients were called PEHO-like patients. PEHO-like patients have a similar clinical disorder, but they do not have cerebellar atrophy on an MRI and lacked ophthalmologic signs [<xref ref-type="bibr" rid="B39-ijms-18-02056">39</xref>]. They showed no reduction in CSF levels. </p>
</sec>
<sec id="sec3dot2dot3-ijms-18-02056">
<title>3.2.3. Infantile Neuronal Ceroid Lipofuscinosis (INCL)</title>
<p>Infantile ceroid lipofuscinosis (INCL) is a neurodegenerative disorder characterized by onset in the second year of life with rapid cognitive and motor deterioration. The EEG is isoelectric by the age of 32 months. The gene locus responsible for the disease has been mapped to chromosome 1p32 [<xref ref-type="bibr" rid="B40-ijms-18-02056">40</xref>]. INCL is characterized by generalized cerebral atrophy, strong thalamic hypointensity in the white matter and the basal ganglia, and thin periventricular high-signal rims as shown by a T2-weighted MRI. Since diffuse cerebral gyral atrophy is so severe, the brain superficially resembles a walnut at autopsy. The brain is characterized by intralysomal accumulation of autofluorescent material mainly composed by sphingolipid activator proteins A and D, which is a secondary phenomenon [<xref ref-type="bibr" rid="B41-ijms-18-02056">41</xref>]. </p>
<p>Palmitoyl protein thioesterase (PPT) is a lysosomal enzyme that hydrolyses acyl chains from fatty “acylated” oproteins and peptides and is especially abundant in neurons [<xref ref-type="bibr" rid="B40-ijms-18-02056">40</xref>]. Normal PPT activity is essential for the normal development of cortical neurons. INCL has been shown to result from a PPT deficiency. Many myelin proteins have been shown to be “pregnylated” and “palmitylated” [<xref ref-type="bibr" rid="B42-ijms-18-02056">42</xref>] (p. 2660). Whether there is modulation of protein “palmitylation” by growth factors remains to be investigated.</p>
<p>In our study, the earliest signs of INCL were seen in all the patients including deceleration of head growth (mean age, 9.5 months), specific EEG changes and typical MRI findings [<xref ref-type="bibr" rid="B43-ijms-18-02056">43</xref>]. </p>
<p>In this neurodegenerative disease, myelination of the white matter starts and may continue in the normal way until at least five months of age, but begins to deviate before the appearance of clinical symptoms and before the age of 13 months, as revealed by quantitative assessment [<xref ref-type="bibr" rid="B43-ijms-18-02056">43</xref>]. Loss of axons and myelin is due mainly to Wallerian degeneration [<xref ref-type="bibr" rid="B44-ijms-18-02056">44</xref>]. Increased white matter interstitial fluid, and abnormal gliosis are thought to account for the white matter intensity seen in an MRI.</p>
<p>Riikonen et al. [<xref ref-type="bibr" rid="B45-ijms-18-02056">45</xref>] suggested that insulin-like growth hormones and apoptosis might play a role in the pathogenesis of INCL. As noted above, IGF-1 levels are associated with an increased number of oligodendrocytes and myelin sheath production. IGF-1 is also anti-apoptotic and a survival factor for oligodendrocyte precursors [<xref ref-type="bibr" rid="B4-ijms-18-02056">4</xref>]. Therefore, a decreased brain production (or supply) of IGF-1 might be responsible for the increased apoptosis. For these reasons, IGF-1 and IGFBP-3 in CSF were measured. The measurements were made at an early stage (19 months). On T2-weighted images, the difference between the cortex and white matter was diminished. Low CSF IGF-1 but normal IGFBP-3 were found in patients with INCL compared with age-matched control subjects. Also, apoptotic cell death was shown in biopsies of INCL patients using terminal deoxynucleotidyl transferase (dUTP) nick end labelling (TUNEL) staining method. Autopsy specimens were taken by brain biopsy during the 1970s for diagnostic purposes when the knowledge of INCL was poor and only a rapidly progressive encephalopathy was diagnosed. In the autopsy brain specimens, in contrast, apoptosis was hardly detectable, probably reflecting the final stage of the disease, when the cellular destruction of tissue has come to an end, and hypertrophic microglia filled the tissue.</p>
<p>Given that, as stated above, the IGF system is important for early brain development, myelination, and neuroprotection (preventing apoptosis), it was suggested that the pathology in INCL might be associated with low CSF IGF-1.</p>
<p>The low IGF-1 values seem not to be specific for INCL. In our study, we showed low CSF IGF-1 in patients with progressive cerebellar diseases, including PEHO syndrome and other forms of progressive cerebellar atrophies with severe neurological involvement [<xref ref-type="bibr" rid="B36-ijms-18-02056">36</xref>].</p>
<p>In another study, we showed that IGF-1 accumulates in the brain of CLN<sup>−/−</sup> knockout mice. IGF-1 accumulated in the brain with or without the complex at all studied time points. The amount crossing the blood brain barrier (BBB) was low but might, however, be sufficient to affect the physiological functions and behaviour of the subjects. Administration of protein binding-3 (PB-3) conjugated IGF-1 and IGF-1/nanoparticles gives a steadier accumulation than unbound IGF-1. Constant and sustained release may increase the bioavailability and therapeutic feasibility of IGF-1 [<xref ref-type="bibr" rid="B46-ijms-18-02056">46</xref>].</p>
<p>Because of the very rapid progressive course of the disease, patients with INCL could be ideal candidates for IGF-1 therapy. The potential effects of the treatment would be seen early clinically, electro-clinically and neuro-radiologically.</p>
</sec>
<sec id="sec3dot2dot4-ijms-18-02056">
<title>3.2.4. Autism</title>
<p>There are no treatments for the core social impairment of autistic spectrum disorder. Current treatments are directed at associated symptoms. There is now more knowledge on emerging mechanism-based therapies [<xref ref-type="bibr" rid="B47-ijms-18-02056">47</xref>,<xref ref-type="bibr" rid="B48-ijms-18-02056">48</xref>].</p>
<p>Autism is a heterogeneous condition, both in its genotype and phenotype. There are hundreds of genetic variants involved in the causation of idiopathic autism. Monogenic diseases are RTT, Fragile X syndrome, and <italic>SHANK</italic> 3 gene deficiency (Phelan–Mc Dermic syndrome).</p>
<p>A fundamental question is whether common underlying molecular pathways exist in ASD. The genes implicated in the development of autism are primarily related to synaptic and immune function [<xref ref-type="bibr" rid="B49-ijms-18-02056">49</xref>]. “Dysregulation of activity-dependent signalling networks may have a key role in the etiology of ASD” [<xref ref-type="bibr" rid="B50-ijms-18-02056">50</xref>] (p. 328). In autism there is aberrant control of synapse formation. It is suggested that IGF-1 increases (normalizes) IGF-1 levels which are reduced in autism at an early stage of the disease [<xref ref-type="bibr" rid="B51-ijms-18-02056">51</xref>,<xref ref-type="bibr" rid="B52-ijms-18-02056">52</xref>].</p>
<sec>
<title>Head Growth in Autism</title>
<p>In autism, many studies show hippocampal, cerebellar or frontal developmental abnormalities. Disorganized cortical patches suggest a prenatal origin of autism. Dysgenetic brain development is thought to begin before 30 weeks of gestation [<xref ref-type="bibr" rid="B53-ijms-18-02056">53</xref>], perhaps through “a signalling abnormality of some neurotrophic factor, or aberrant programmed cell death” [<xref ref-type="bibr" rid="B54-ijms-18-02056">54</xref>] (p. 10). In post-mortem specimens of individuals with autism there is evidence of decreased numbers of cerebellar Purkinje cells. Histological studies suggest that this reduction is prenatal in origin [<xref ref-type="bibr" rid="B54-ijms-18-02056">54</xref>,<xref ref-type="bibr" rid="B55-ijms-18-02056">55</xref>]. Post-mortem studies also support the hypothesis that there is a combination of abnormal excess and reduction at the microstructural level ([<xref ref-type="bibr" rid="B56-ijms-18-02056">56</xref>,<xref ref-type="bibr" rid="B57-ijms-18-02056">57</xref>], p. 157). </p>
<p>Several pathological studies have reported increased brain weight and cerebral volume in individuals with autism [<xref ref-type="bibr" rid="B58-ijms-18-02056">58</xref>,<xref ref-type="bibr" rid="B59-ijms-18-02056">59</xref>,<xref ref-type="bibr" rid="B60-ijms-18-02056">60</xref>,<xref ref-type="bibr" rid="B61-ijms-18-02056">61</xref>,<xref ref-type="bibr" rid="B62-ijms-18-02056">62</xref>,<xref ref-type="bibr" rid="B63-ijms-18-02056">63</xref>]. Head size was increased in about a quarter of patients.</p>
<p>In neonates with later ASD, head circumference at birth has been found to be normal or slightly below average, and then followed by early overgrowth during the first one or two years. However, growth abruptly slowed down thereafter and the brain volumes have been reported to be smaller than those of normal controls in their adulthood [<xref ref-type="bibr" rid="B57-ijms-18-02056">57</xref>]. In longitudinal MRI studies with multiple scans from two years of age followed up until 4–5 years. Shen et al. demonstrated enlargement at age two years with no increase in growth rate during the subsequent two years [<xref ref-type="bibr" rid="B64-ijms-18-02056">64</xref>]. Increased brain volume may therefore be the result of overgrowth occurring prior to the age of two years. Furthermore, according to Hazlett et al. hyper-expansion of the cortical surface area between six and 12 months of age proceed the brain volume overgrowth observed between 12 and 24 months in “high-risk” infants (infants with an older sibling with autism) who were diagnosed with autism at 24 months [<xref ref-type="bibr" rid="B65-ijms-18-02056">65</xref>]. A deep-learning algorithm that primarily uses information on the surface areas of the brain in 6–12-month-old children predicted the diagnosis of autism in high-risk children at 24 months [<xref ref-type="bibr" rid="B65-ijms-18-02056">65</xref>]. In this study it was demonstrated that early brain changes occur during the period in which autistic behaviours first emerge [<xref ref-type="bibr" rid="B65-ijms-18-02056">65</xref>].</p>
<p>Herbert et al. suggest that the enlargement of the brain develops postnatally and is caused by a temporally modulated process. The distribution of volume changes suggests a process that alters some non-axonal component of white matter, possibly myelin. In the study by Courchesne and Pierce [<xref ref-type="bibr" rid="B57-ijms-18-02056">57</xref>], the brain overgrowth was most prominent in the frontal and temporal lobes and in the amygdala, and more apparent in grey matter than in white matter. These patterns of enlargement are consistent with postnatal increases reported in autism. More recently, Hazlett et al. found in a longitudinal MRI study generalized cerebral cortical enlargement with disproportionate enlargement of temporal lobe white matter in the ASD group in two-year-old children [<xref ref-type="bibr" rid="B66-ijms-18-02056">66</xref>].</p>
<p>It is unknown what causes abnormal head growth in autism. Early rapid postnatal overgrowth is deleterious because it coincides with the time of the development of intensive cortical synaptic connections. In autism there seems to be a disruption of normal neurobiological mechanisms leading to “premature growth without guidance” [<xref ref-type="bibr" rid="B57-ijms-18-02056">57</xref>] (p. 157). </p>
</sec>
<sec>
<title>CSF IGF-1 and IGF-2 in Autism </title>
<p>The parents and other caregivers usually become aware of the aberrant development during the child’s second year of age. The diagnosis is based on clinical criteria and is usually made at age 3–4 years. Normal neurobiological processes are disturbed but it is not known what specific developmentally-important molecules might be involved in this disorder. Nelson et al. suggested that there is a relationship between abnormal growth factors (BDNF) in autism and abnormal brain growth patterns [<xref ref-type="bibr" rid="B67-ijms-18-02056">67</xref>]. However, when the same samples were later re-evaluated with a better method, no differences existed between BDNF concentrations in children with autism and normal controls.</p>
<p>In our study of autistic children we measured the CSF and serum concentrations of some neurotrophic factors, such as β-neurotrophic factor (NGF), brain-derived nerve growth factor (BDNF)<italic>,</italic> IGF-1, and IGF-2 from serum and cerebrospinal fluid by radio-immunoassay (except for BDNF). However, the levels of BDNF in the CSF were below the limit of sensitivity of the methods used. Serum BDNF levels showed a bimodial distribution of either high or low. Of the other measures, only CSF IGF-1 differed between children with autism and normal children.</p>
<p>The diagnosis of the patients with autism was based on multi-disciplinary studies, and the criteria of autism were defined by International Classification of Diseases -10 (ICD-10) (World Health Organization, 1993) and Diagnostic and Statistical Manual of Mental Disorders (DMS-IV) (American Psychiatric Association, 2000) criteria. Patients were admitted to the Hospital for Children and Adolescents, Helsinki, and Department of Paediatrics, Unit of Child Neurology, Kuopio University Hospital, Kuopio, Finland. All the patients underwent extensive etiological studies. The autism of these children was considered to be idiopathic. The mean IQ of the patients was 80.</p>
<p>In the first study, in 11 children younger than five years we found low CSF IGF-1 concentrations compared to age-matched controls with neurological disorders. There was no difference in the IGF-2 concentrations between the two groups. None of the controls exhibited any signs of malnutrition, hepatic failure, chronic inflammation, diabetes, or hypothyroidism (conditions which might have affected the IGF-1 levels) [<xref ref-type="bibr" rid="B51-ijms-18-02056">51</xref>]. In a larger study, we studied 26 autistic children with (median age five years and five months; range one year and 11 months to 15 years and 10 months), and 16 age-matched controls. We found that CSF IGF-1 concentrations were low in autism, but only at an early age and not in older children [<xref ref-type="bibr" rid="B52-ijms-18-02056">52</xref>]. In this study we used “healthy” age-matched controls, children who underwent surgery with spinal anaesthesia.</p>
<p>Head circumference is a practical measure of brain size during the first years of life. Records are available for height, weight and head circumference from birth to the date of measurement of CSF IGF-1 in our cohort. There was no evidence of macrocephaly at the time of CSF sampling (mean age 5.5 years). Pathological brain growth is largely restricted to the first 1–3 years of life which is typically prior to the diagnosis of autism. We did not measure CSF IGF-1 at the age when the children showed acceleration of head growth from birth to 3 to 6 months of age. However, we found a positive correlation between head growth (head circumference) and CSF-1 IGF concentrations in children with autism but not in the control group [<xref ref-type="bibr" rid="B52-ijms-18-02056">52</xref>].</p>
</sec>
<sec>
<title>Cerebellum and Autism</title>
<p>In autism, many studies show hippocampal or cerebellar developmental abnormalities. One of the most consistently abnormal brain regions has been shown to be the cerebellum. Almost all of the postmortem brains of autistic individuals studied to date have shown a significant decrease in the number of Purkinje cells [<xref ref-type="bibr" rid="B54-ijms-18-02056">54</xref>,<xref ref-type="bibr" rid="B56-ijms-18-02056">56</xref>,<xref ref-type="bibr" rid="B58-ijms-18-02056">58</xref>]. Morphological and electrophysiological defects in Purkinje cells are linked to system-wide ASD-like behaviour [<xref ref-type="bibr" rid="B68-ijms-18-02056">68</xref>]. Loss of Tsc2 in Purkinje cells was associated with autistic-like behaviour in a mouse model of tuberous sclerosis and social behaviour deficits were prevented by rapamycin treatment [<xref ref-type="bibr" rid="B69-ijms-18-02056">69</xref>]. These findings define a molecular mechanism for a cerebellar contribution to cognitive disorders such as autism.</p>
<p>As described before, there is evidence that IGF-1 is essential to cerebellar development and Purkinje cell survival [<xref ref-type="bibr" rid="B70-ijms-18-02056">70</xref>,<xref ref-type="bibr" rid="B71-ijms-18-02056">71</xref>]. Gene expression of IGF-1 has been detected in Purkinje cells and other neurons in the developing cerebellum. Low CSF IGF-1 concentrations in children with autism may point to cerebellar abnormalities. </p>
<p>Accumulating evidence indicates that the cerebellum is involved in shifting attention which in turn is important for social and cognitive development [<xref ref-type="bibr" rid="B72-ijms-18-02056">72</xref>,<xref ref-type="bibr" rid="B73-ijms-18-02056">73</xref>]. Disordered attention is strongly characteristic of autism at a very early age but becomes less prominent with maturation [<xref ref-type="bibr" rid="B74-ijms-18-02056">74</xref>]. This change is in a temporal relationship with the unusual trajectory of brain growth [<xref ref-type="bibr" rid="B60-ijms-18-02056">60</xref>,<xref ref-type="bibr" rid="B62-ijms-18-02056">62</xref>]. In preterm infants with cerebellar damage (haemorrhage) there is a high prevalence of autism [<xref ref-type="bibr" rid="B75-ijms-18-02056">75</xref>]. Low concentrations of IGF-1 during the critical brain spurt period might be insufficient for survival of normal Purkinje cells in the cerebellum. An early reduction of Purkinje cells may result in significantly reduced cerebellar activation. </p>
<p>The cerebellum is structurally and functionally abnormal in autistic patients, as shown in many studies. </p>
<p>Moreover, IGF-1 and related physiology have been implicated in disorders causing progressive cerebellar dysfunction [<xref ref-type="bibr" rid="B36-ijms-18-02056">36</xref>,<xref ref-type="bibr" rid="B70-ijms-18-02056">70</xref>]. </p>
<p>Mills et al. have reported elevated serum levels of growth hormones (including IGF-1) in 71 children aged 4–8 years with autism and autism spectrum disorder [<xref ref-type="bibr" rid="B76-ijms-18-02056">76</xref>]. This is not in discrepancy with our findings of low CSF IGF-1 in younger children and normal values in older children. In the study that we carried out in Finland, no correlation was detected between the serum and CSF concentrations of IGFs, thus the findings cannot be directly compared with those of the Finnish study. Furthermore, there was a difference in patient and control selection between the two studies [<xref ref-type="bibr" rid="B77-ijms-18-02056">77</xref>]. However, both studies found a significant correlation between IGF-1 levels (in the latter study serum and in our study CSF concentrations) [<xref ref-type="bibr" rid="B52-ijms-18-02056">52</xref>] and head circumference in autistic children and controls.</p>
</sec>
<sec>
<title>Serotonin and IGF in Autism</title>
<p>There is evidence for a key role of disturbances of the serotoninergic system in autism [<xref ref-type="bibr" rid="B78-ijms-18-02056">78</xref>,<xref ref-type="bibr" rid="B79-ijms-18-02056">79</xref>,<xref ref-type="bibr" rid="B80-ijms-18-02056">80</xref>]. Serotonin has been shown to act as an early regulator of brain development. Selective serotonin uptake inhibitors (SERTIs) increased the synthesis of neurotrophic factors and improved symptoms of autism in some studies [<xref ref-type="bibr" rid="B81-ijms-18-02056">81</xref>,<xref ref-type="bibr" rid="B82-ijms-18-02056">82</xref>,<xref ref-type="bibr" rid="B83-ijms-18-02056">83</xref>,<xref ref-type="bibr" rid="B84-ijms-18-02056">84</xref>]. The brain SERT is responsible for active reuptake of serotonin molecules from the synapses, and SERT was shown to be the exact site of action of these drugs. It increases serotonin availability at synapses. To our knowledge there are no published studies on the serotonin transporter (SERT) on the brain in patients with autism. We found reduced SERT binding in the medial frontal cortex, midbrain and temporal lobes using single photon emission computed tomography (SPECT) with iodine-123 labelled <italic>N</italic>-(2-fluoroethyl)-2β-carbomethoxy-3β-(4-iodyphenyl)-nortropane ([<sup>123</sup>I] nor-β-CIT) [<xref ref-type="bibr" rid="B85-ijms-18-02056">85</xref>]. This finding confirms the suspicion that there is disruption to serotonergic dysfunction in autism. An early decrease in serotoninergic neurons could lead to low brain concentrations of IGFs, which, once more, are critical for Purkinje cell development.</p>
<p>In summary, how these findings fit with the phase of brain development is unclear. Low CSF IGF-1 concentrations in children with autism at an early age may suggest a disruption of normal neurobiological mechanisms in this period. To our knowledge, our study was the first to suggest that IGF concentrations may be important in the pathogenesis of autism.</p>
<p>Furthermore, Anlar et al. demonstrated that IGF-1 levels in urine were significantly lower in autistic than in age-matched controls [<xref ref-type="bibr" rid="B86-ijms-18-02056">86</xref>].</p>
</sec>
</sec>
<sec id="sec3dot2dot5-ijms-18-02056">
<title>3.2.5. Rett Syndrome</title>
<p>It has been argued that Rett syndrome (RTT) is in fact a neurodevelopmental condition rather than a neurodegenerative condition. One piece of evidence for this is that mice with induced RTT show no neuronal death. There is also lack of neurodegenerative changes in postmortem brains. RTT is a disease of synaptic dysfunction [<xref ref-type="bibr" rid="B87-ijms-18-02056">87</xref>,<xref ref-type="bibr" rid="B88-ijms-18-02056">88</xref>]. </p>
<p>At the onset, the two conditions, RTT and autism, overlap widely. To differentiate between RTT and infantile autism in the very early stages of the disorders was not always clinically easy before the MECP2 mutation in RTT was found. However, there are a number of differences in the two syndromes, such as <italic>head growth</italic>: microcephaly in RTT [<xref ref-type="bibr" rid="B89-ijms-18-02056">89</xref>], normal or macrocephaly in autism [<xref ref-type="bibr" rid="B57-ijms-18-02056">57</xref>]; <italic>neurons</italic>: cholinergic neurons are affected in RTT [<xref ref-type="bibr" rid="B90-ijms-18-02056">90</xref>], serotoninergic neurons are affected in autism [<xref ref-type="bibr" rid="B91-ijms-18-02056">91</xref>]; <italic>neuropathology</italic>: frontal cortex pathology in RTT [<xref ref-type="bibr" rid="B89-ijms-18-02056">89</xref>], cerebellum and hippocampus pathology in autism [<xref ref-type="bibr" rid="B54-ijms-18-02056">54</xref>,<xref ref-type="bibr" rid="B55-ijms-18-02056">55</xref>,<xref ref-type="bibr" rid="B92-ijms-18-02056">92</xref>]; <italic>onset</italic>: postnatal onset in RTT [<xref ref-type="bibr" rid="B87-ijms-18-02056">87</xref>], early prenatal origin in autism beginning before 28–30 weeks of gestational age, according to earlier reported findings examining the connections of Purkinje cells with other brain structures [<xref ref-type="bibr" rid="B53-ijms-18-02056">53</xref>]. In RTT, the forebrain is more severely affected than other cortical areas. The basal forebrain shows reduced volume [<xref ref-type="bibr" rid="B55-ijms-18-02056">55</xref>,<xref ref-type="bibr" rid="B93-ijms-18-02056">93</xref>], reduced cholinergic neurons [<xref ref-type="bibr" rid="B89-ijms-18-02056">89</xref>] reduced acetyl transferase [<xref ref-type="bibr" rid="B90-ijms-18-02056">90</xref>], low NGF concentrations post-mortem [<xref ref-type="bibr" rid="B94-ijms-18-02056">94</xref>], and hypometabolism of the basal forebrain [<xref ref-type="bibr" rid="B95-ijms-18-02056">95</xref>]. In our study, patients with RTT had low levels of CSF NGF [<xref ref-type="bibr" rid="B96-ijms-18-02056">96</xref>] which is consistent with the evidence for loss of basal forebrain cholinergic neurons in RTT. In autism, the cerebellum and hippocampus are abnormal [<xref ref-type="bibr" rid="B54-ijms-18-02056">54</xref>,<xref ref-type="bibr" rid="B80-ijms-18-02056">80</xref>], and the serotoninergic transmission is disturbed [<xref ref-type="bibr" rid="B78-ijms-18-02056">78</xref>].</p>
<p>We have evaluated serum and CSF concentrations of NGF, BDNF, glial cell line-derived nerve growth factor (GDNF), IGF-1 and IGF-2 in RTT. However, the levels of BDNF and GDNF in the CSF were below the limit of sensitivity of the methods used.Our findings of mainly normal CSF NGF in autism, low to negligible values in RTT, decreased IGF-1 in autism and normal values in RTT, agree with the different morphological and neurochemical findings in the two syndromes [<xref ref-type="bibr" rid="B97-ijms-18-02056">97</xref>].</p>
</sec>
</sec>
<sec id="sec3dot3-ijms-18-02056">
<title>3.3. Subacute Sclerosing Panecephalitis and Over-Expression of IGF-1 in Advanced Stage</title>
<p>Subacute sclerosing panencephalitis (SSPE), also known as measles encephalitis, is a rare and chronic form of progressive brain inflammation caused by a persistent infection with the measles virus. Higher IGF-1 levels in CSF of advanced SSPE (stage four) have been found, as compared to other stages of the disease [<xref ref-type="bibr" rid="B98-ijms-18-02056">98</xref>]. Both CSF insulin and IGF-1 levels were positively correlated with serum measles immunoglobulin G (IgG). EEG abnormalities were associated with higher tau protein levels and brain autopsy studies show neurofibrillary tangles associated with tau protein. Further studies will reveal whether there are possible pathogenetic relations between IGF-1, measles IgG titers and tau protein in SSPE [<xref ref-type="bibr" rid="B98-ijms-18-02056">98</xref>].</p>
</sec>
</sec>
<sec id="sec4-ijms-18-02056">
<title>4. IGF-Based Therapeutic Strategies</title>
<p>In animal models, IGF-1 overexpression enhanced neurogenesis and maturation, and accelerated recovery following traumatic injury [<xref ref-type="bibr" rid="B99-ijms-18-02056">99</xref>]. In post-traumatic injury, as in several pathologies of the CNS, inflammation of the brain, abnormal microglial function, synaptic dysfunction and decreased levels of IGF-1 coexist. Therefore, increasing IGF-1 levels in the brain might be useful for treating a number pathologies, including neurodevelopmental disorders and neurodegenerative diseases. </p>
<p>Treatment with IGF-1 may similarly be applicable to autism-spectrum disorders for a wide range of symptoms such as memory, anxiety, hyperactivity, seizures and social behavior. In fact, defects in neuronal networks could be rescued by IGF-1, as shown in animal studies [<xref ref-type="bibr" rid="B100-ijms-18-02056">100</xref>,<xref ref-type="bibr" rid="B101-ijms-18-02056">101</xref>,<xref ref-type="bibr" rid="B102-ijms-18-02056">102</xref>]. Moreover, there is now a clinical trial underway in which IGF-1 is being used for treatment of autism [<xref ref-type="bibr" rid="B103-ijms-18-02056">103</xref>].</p>
<p>Therefore, normalizing IGF-1 levels might be one of the effects of IGF-1 therapy [<xref ref-type="bibr" rid="B104-ijms-18-02056">104</xref>]. As stated above, functional defects in neuronal networks could be rescued by IGF [<xref ref-type="bibr" rid="B103-ijms-18-02056">103</xref>]. IGF-1 reduces neuroinflammation by decreasing secretion of cytokines such as interleukin 6 (IL6) and alters microglial function, thereby reducing the defects in the synapses [<xref ref-type="bibr" rid="B23-ijms-18-02056">23</xref>,<xref ref-type="bibr" rid="B100-ijms-18-02056">100</xref>,<xref ref-type="bibr" rid="B105-ijms-18-02056">105</xref>,<xref ref-type="bibr" rid="B106-ijms-18-02056">106</xref>,<xref ref-type="bibr" rid="B107-ijms-18-02056">107</xref>]. In autism there is aberrant control of synapse formation [<xref ref-type="bibr" rid="B23-ijms-18-02056">23</xref>]. IGF-1 alleviates <italic>N</italic>-methyl-<sc>d</sc>-asparate (NMDA)-induced neurotoxicity via the IGF AKT (protein kinase B) -mammalian target of rapamycin (AKT-mTor pathway) [<xref ref-type="bibr" rid="B102-ijms-18-02056">102</xref>]. This pathway is dysregulated in autism. IGF-1 may rescue function in RTT and ASD caused by changes of the SHANK3 gene [<xref ref-type="bibr" rid="B108-ijms-18-02056">108</xref>,<xref ref-type="bibr" rid="B109-ijms-18-02056">109</xref>,<xref ref-type="bibr" rid="B110-ijms-18-02056">110</xref>], and reverse the reduction in excitatory synapse numbers [<xref ref-type="bibr" rid="B111-ijms-18-02056">111</xref>].</p>
</sec>
<sec id="sec5-ijms-18-02056">
<title>5. What Are the Therapeutic Approaches?</title>
<p>During the last decade, there has been a dramatic increase in research aimed at treating neurodevelopmental disorders. These efforts have been the consequence of a better understanding of cellular mechanisms and the genetic basis of several of these disorders and the subsequent development of experimental models, primarily mouse models. The potential role of IGF-1 therapy would be in preventing neuronal injury, reducing neuronal degeneration and increasing myelination. In animals, IGF-1 has been shown to be effective in motor neuron disorder, neuropathy, cerebellar ataxia, ceroid lipofuscinosis; retinopathy of prematurity, and cognitive impairment in early autoimmune encephalopathy.</p>
<p>IGF-1 has been identified to have a crucial role in normal CNS development. Several clinical studies have suggested a potential role for IGF-1 in the treatment of disorders of CNS, including ASD. The focus of the recent studies has been to develop novel, targeted, and potentially disease modifying therapeutics in CNS diseases in children.</p>
<p>The major problems are the following: (1) Does enough IGF-1 cross the BBB? (2) Can the action of the drugs be lengthened? (3) Can we make the neurons active? (4) Are there serious side-effects?</p>
<p>Studies of RTT both in mouse models and humans show benefits of treatments with IGF-1, raising the possibility that this compound may have benefits broadly in ASD, despite the different molecular aetiology. Given the extensive safety data of IGF-1 therapy for IGF-1 deficiency-related short stature and a recent RTT study, IGF-1 is a good potential candidate for controlled trials in ASD [<xref ref-type="bibr" rid="B112-ijms-18-02056">112</xref>,<xref ref-type="bibr" rid="B113-ijms-18-02056">113</xref>]. </p>
<sec id="sec5dot1-ijms-18-02056">
<title>5.1. What Is the Current Status of IGF-1 Treatment?</title>
<p>Recombinant human IGF-1 (mecasermin) was developed for the treatment of children with growth failure because of deficient IGF-1 liver production due to mutations or deletion of the hepatic growth hormone receptor [<xref ref-type="bibr" rid="B114-ijms-18-02056">114</xref>,<xref ref-type="bibr" rid="B115-ijms-18-02056">115</xref>]. The treatment has to be given until the end of puberty, when growth stops due to the ossification of the growth cartilage. Its commercial name is Increlex<sup>®</sup> and it is given by subcutaneous injection. The main adverse effect of mecasermin is the risk of inducing hypoglycemia (it mimics most of the actions of insulin), and can have mitogen effects if given long-term [<xref ref-type="bibr" rid="B116-ijms-18-02056">116</xref>]. Another problem is that it crosses with difficulty the BBB.</p>
<p>Despite these problems, IGF-1 has been used in patients with RTT (<italic>n</italic> = 6, aged 4–11 years), at doses of 0.05–0.1 mg/kg twice per day for six months, without significant adverse effects [<xref ref-type="bibr" rid="B117-ijms-18-02056">117</xref>]. In this small pilot study, the parents of the patients observed that children with RTT showed improvement in cognition and social interaction. Two years later, the same group published the evolution of a RTT patient who was treated at the age of five years and eight months, with a first cycle of IGF-1 for four months and then two years later the same treatment was repeated [<xref ref-type="bibr" rid="B118-ijms-18-02056">118</xref>]. Curiously, while scores from tests analyzing cognition and social abilities improved after each cycle, these achievements were lost during the two years without treatment. This indicates that the treatment of RTT with IGF-1 has to be maintained long-term. No adverse effects were reported, although the time during which the treatment took place was too short.</p>
<p>In the same year, it was reported that 12 girls with MECP2 mutations, nine of them with RTT, who were treated with IGF-1 experienced improvements in mood and anxiety. These findings were supported by reversal of right alpha band asymmetry on EEG, which is an established index of anxiety and depression. Moreover, these authors did not observe any adverse effects attributable to IGF-1, and also found that CSF IGF-1 levels had increased at the end of treatment period, which indicates that IGF-1 crosses the BBB [<xref ref-type="bibr" rid="B104-ijms-18-02056">104</xref>].</p>
<p>In parallel with the aforementioned studies, a genetic subtype of autism was described [<xref ref-type="bibr" rid="B109-ijms-18-02056">109</xref>]. This subtype of autism is known as Phelan–McDermic syndrome, which is produced by mutations or deletions in a gene, the SCHANK3 gene, located on the chromosome 22q, is responsible for the expression of a protein playing a critical role in synaptic function. Consequently, the loss of the function of that protein leads to a global developmental delay that cause cognitive disabilities, speech affections, hypotonia, and some dysmorphic features. The syndrome causes ASD-like behaviors, and is responsible for at least 0.5% of the cases of ASD. The authors carried out a placebo-controlled, double-blind, cross-over study in nine children (5–15 years old) who presented this syndrome, treating them with IGF-1 over three months, followed by three months of placebo after a four-week wash-out period. Before commencing the treatment and after finishing it, social impairments and restrictive behaviors, typical of the syndrome, were evaluated by the aberrant behavior checklist and the repetitive behaviour scale. Interestingly, after being treated with IGF-1 both scales showed significant improvements in the parameters evaluated, however these were not maintained after interrupting IGF-1 treatment [<xref ref-type="bibr" rid="B109-ijms-18-02056">109</xref>].</p>
<p>A clinical trial with rhIGF-1 in children with Phelan–McDermic syndrome is currently underway ((ClinicalTrials. gov. Identifier: NCT0152901). IGF-1 (1–3) (NNZ-2566) Trofineitide, Neuren Pharmaceuticals).</p>
<p>Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1. Endogenous peptidase enzymes cleave IGF-1, separating the terminal tripeptide IGF-1 (1–3). This peptide has been modified by methylation of glycine, allowing the drug to be administered orally or intravenously for a range of acute and chronic conditions. </p>
<p>It crosses the BBB and easily enters into the brain. IGF-1 (1–3) does not bind directly to the IGF-1 receptors, but it acts through the IGF-1 receptor. IGF-1 (1–3) induces an increase in the production of IGF-1, which in turn activates the IGF-1 receptor [<xref ref-type="bibr" rid="B23-ijms-18-02056">23</xref>]. This weak binding might mean that it is not a mitogen. The results also suggest that there is a direct interaction between both molecules.</p>
<p>IGF-1 (1–3) has considerably reduced binding to the IGFBPs, which results in an enhanced potency (about 10-fold in vivo) relative to IGF-1. This results in an increased prolongation of potential adverse events like hypoglycaemia [<xref ref-type="bibr" rid="B119-ijms-18-02056">119</xref>]. However, NNZ-2566, Trofinetide is well-tolerated, and is currently being studied in clinical trials in at least two neurodevelopmental disorders, RTT (ClinicalTrials. gov. Identifier: NCT01703533) and Fragile X syndrome (FXS; ClinicalTrials. gov. Identifier: NCT01894958). It has been shown to rescue function of MECP2 in mouse model of RTT syndrome [<xref ref-type="bibr" rid="B101-ijms-18-02056">101</xref>]. Since it has successfully passed Phase III clinical trials in adults, and is being studied in Phase II trials in children, it is expected that soon this new drug will be commercially available.</p>
</sec>
<sec id="sec5dot2-ijms-18-02056">
<title>5.2. Longevity of the Therapy and Long-Term Adverse Effects</title>
<sec id="sec5dot2dot1-ijms-18-02056">
<title>5.2.1. How Long Should IGF-1 Therapy Be Used?</title>
<p>RTT syndrome is produced by mutations in the gene MECP2 encoding x-linked methyl CpCbinding protein. Therefore, it is likely that only a gene therapy would be able to revert this syndrome. However, treatments with IGF.1 have been shown to produce functional recoveries in MECP2 mutant mice [<xref ref-type="bibr" rid="B120-ijms-18-02056">120</xref>], and, as described before, IGF-1 (1-3) administration induced partial reversal of RTT-like symptoms in humans [<xref ref-type="bibr" rid="B101-ijms-18-02056">101</xref>]. However, the symptoms come back when the treatment is interrupted [<xref ref-type="bibr" rid="B118-ijms-18-02056">118</xref>], which suggests that in this situation IGF-1 acts by epigenetic mechanisms. Since the disease begins early in postnatal life, it has been suggested that maintaining MECP2 function during the first stages of life might provide a kind of protection for preventing the apparition of the disease later in life. However, this has been proved to be not effective, as demonstrated by the McGraw group in an inducible model of RTT in which they improved the functionality of MECP2 during early postnatal life [<xref ref-type="bibr" rid="B121-ijms-18-02056">121</xref>]. Therefore, the need exists for continuous IGF-1 administration to alleviate the symptoms of the disease, at least, until Trofinetide will be available. </p>
</sec>
<sec id="sec5dot2dot2-ijms-18-02056">
<title>5.2.2. Long-Term Side-effects</title>
<p>Although IGF-1 holds therapeutic promise, it may produce undesirable side effects and it must be used with caution. There seems to be an association between genetic variations in IGF-1 signalling pathways and cancer. High levels of circulating IGF-1 and certain genetic polymorphisms of IGF-1 and IGFBP3 increase the risk of several common cancers [<xref ref-type="bibr" rid="B122-ijms-18-02056">122</xref>,<xref ref-type="bibr" rid="B123-ijms-18-02056">123</xref>]. IGF-1 may also increase the risk of an abnormal metabolism and diabetes [<xref ref-type="bibr" rid="B124-ijms-18-02056">124</xref>]. However, states of relative IGF-1 deficiency seem to be protective against cancer [<xref ref-type="bibr" rid="B125-ijms-18-02056">125</xref>]. When plasma levels IGF-1 are low, mitogen effects seem not to occur. If hypoglycaemia occurs with recommended doses despite adequate food intake, the dose should be reduced. IGF-1 should be administered shortly before or after (±20 min) a meal or snack. During treatment with IGF-1 it is recommended to monitor its plasma concentration periodically, ensuring that its concentration does not markedly exceed 2 SD over the mean for the age of the patient, according the reference ranges [<xref ref-type="bibr" rid="B126-ijms-18-02056">126</xref>].</p>
</sec>
</sec>
<sec id="sec5dot3-ijms-18-02056">
<title>5.3. Timing of Therapy</title>
<p>In the U.S. positive results have been reported by Neuren Pharma in adults with RTT treated with Trofinetide. Fifty-three patients aged 16 to 45 years completed the double-blind placebo-controlled trial. Of the six measures to ascertain change after treatment with the drug, three indicated a change for the better. Measures of impressions of motor behaviour involvement, and of the caregivers’ top three concerns, met the criteria of improvement, as reviewed by Pozzo-Miller et al. [<xref ref-type="bibr" rid="B127-ijms-18-02056">127</xref>].</p>
<p>The drug should probably be given at an early age when there is a deficiency of IGF-1 in autism [<xref ref-type="bibr" rid="B51-ijms-18-02056">51</xref>,<xref ref-type="bibr" rid="B52-ijms-18-02056">52</xref>] and synaptic development is more active. The pathological process should be stopped at an early age before irreversible nerve growth damage occurs.</p>
</sec>
</sec>
<sec id="sec6-ijms-18-02056">
<title>6. Conclusions</title>
<p>IGF-1 may be involved in the pathogenesis of some neurodevelopmental (RTT), and neurodegenerative diseases (PEHO, INCL, cerebellar degeneration and SSPE). IGF-1 may be neuroprotective in preterm infants, and after neonatal ischemic brain injury. In infantile spasms CSF IGF-1 studied at the time of presentation seems to be a biomarker of (1) treatment response and progression of epilepsy, and (2) of later cognitive outcome. Brain growth of autistic children correlates positively with serum and CSF IGF-1 concentrations. In ASD research molecular studies on synaptic dysfunction have proceeded to experimental therapeutics. The precise mechanism by which IGF-1 exerts its effects on the CNS remains an active area of study. Although definitive studies are needed, pilot data suggest that IGF-1 or its analogues are promising for the treatment of the neurodevelopmental disorders associated with ASD.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>No funds for covering the costs to publish in open access. I thank Jesus Devesa (Scientific Director, The Medical Centre, Foltra, Teo, Spain) for rephrasing the text.</p>
</ack>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The author declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-18-02056">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Powel-Braxton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Widmer</surname>
<given-names>H.-R.</given-names>
</name>
<name>
<surname>Valverde</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hefti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>IGF-1 gene distruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal paralbumin-containing neurons</article-title>
<source/>Neuron
          <year>1995</year>
<volume>14</volume>
<fpage>717</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1016/0896-6273(95)90216-3</pub-id>
<pub-id pub-id-type="pmid">7718235</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-18-02056">
<label>2.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Leventhal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Russel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>IGFs and the nervous system</article-title>
<source/>The IGF System: Molecular Biology, Physiology and Clinical Application
          <person-group person-group-type="editor">
<name>
<surname>Rosenfeld</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>C.</given-names>
</name>
</person-group>
<publisher-name>Humana Press, Inc.</publisher-name>
<publisher-loc>Totowa, NJ, USA</publisher-loc>
<year>1999</year>
<fpage>425</fpage>
<lpage>455</lpage>
</element-citation>
</ref>
<ref id="B3-ijms-18-02056">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenle</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Haselbacher</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Briner</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Elevated concentrations of IGFII in brain tissue from an infant with macrocephaly</article-title>
<source/>J. Pediatr.
          <year>1986</year>
<volume>108</volume>
<fpage>737</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(86)81057-5</pub-id>
<pub-id pub-id-type="pmid">3701522</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-18-02056">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barres</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Coles</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Burne</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Voyvodic</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Raff</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Cell death and control of cell survival</article-title>
<source/>Cell
          <year>1992</year>
<volume>70</volume>
<fpage>31</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(92)90531-G</pub-id>
<pub-id pub-id-type="pmid">1623522</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-18-02056">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres-Aleman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Barrios</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bericiano</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The insulin-like growth factor I system in cerebellar degeneration</article-title>
<source/>Ann. Neurol.
          <year>1996</year>
<volume>39</volume>
<fpage>335</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410390310</pub-id>
<pub-id pub-id-type="pmid">8602752</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-18-02056">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dopping</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sand</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Quantitative growth and development of human brain</article-title>
<source/>Arch. Dis. Child.
          <year>1973</year>
<volume>43</volume>
<fpage>757</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="doi">10.1136/adc.48.10.757</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-18-02056">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gluckman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Werther</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The insulin-like growth factor system and its pleiotropic functions in brain</article-title>
<source/>Endocr. Rev.
          <year>2005</year>
<volume>26</volume>
<fpage>916</fpage>
<lpage>943</lpage>
<pub-id pub-id-type="doi">10.1210/er.2004-0024</pub-id>
<pub-id pub-id-type="pmid">16131630</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-18-02056">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mallard</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Gluckman</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor is a potent neuronal rescue agent after hypoxic-ischemic injury in lambs</article-title>
<source/>J. Clin. Investig.
          <year>1996</year>
<volume>97</volume>
<fpage>300</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1172/JCI118416</pub-id>
<pub-id pub-id-type="pmid">8567948</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-18-02056">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Custodio</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>do Carmo Custodio</surname>
<given-names>V.I.</given-names>
</name>
<name>
<surname>Scrideli</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Sader Milani</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Cervi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Cupo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>C.E.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Impact of hypoxia on IGF-1, IGF-II, IGFB-3. ALS and IGFBP-1 regulation and on IGF1R gene expression in children</article-title>
<source/>Growth Horm. IGF Res.
          <year>2012</year>
<volume>22</volume>
<fpage>186</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.ghir.2012.07.001</pub-id>
<pub-id pub-id-type="pmid">22901623</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-18-02056">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verhaeghe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Herck</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Billen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Van Assche</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>Regulation of insulin-like growth factor-I and insulin-like growth factor binding protein-1 concentrations in preterm fetuses</article-title>
<source/>Am. J. Obstet. Gynecol.
          <year>2003</year>
<volume>188</volume>
<fpage>485</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.1067/mob.2003.26</pub-id>
<pub-id pub-id-type="pmid">12592260</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-18-02056">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yeomans</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Elsayed</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Medhurst</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Skuza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>A randomised crossover trial of clinical algorithm for oxygen saturation targeting in preterm infants with frequent desaturation episodes</article-title>
<source/>Neonatology
          <year>2015</year>
<volume>107</volume>
<fpage>130</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1159/000368295</pub-id>
<pub-id pub-id-type="pmid">25531240</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-18-02056">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen-Pupp</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hellstrom-Westas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cilio</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fellman</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Inflammation at birth and the insulin-like growth factor system in very preterm infants</article-title>
<source/>Acta Paediatr.
          <year>2007</year>
<volume>96</volume>
<fpage>830</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.1111/j.1651-2227.2007.00276.x</pub-id>
<pub-id pub-id-type="pmid">17465986</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-18-02056">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papastathi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mavrommatis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mentzelopoulos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Konstandelou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alevizaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zakynthinos</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Insulin-like Growth Factor I and its binding protein 3 in sepsis</article-title>
<source/>Growth Horm. IGF Res.
          <year>2013</year>
<volume>23</volume>
<fpage>98</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1016/j.ghir.2013.03.005</pub-id>
<pub-id pub-id-type="pmid">23611528</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-18-02056">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hellström</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hansen-Pupp</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hallberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Löfqvist</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Van Marter</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>van Weissenbruch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramenghi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beardsali</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dunger</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development</article-title>
<source/>Acta Pediatr.
          <year>2016</year>
<volume>105</volume>
<fpage>576</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1111/apa.13350</pub-id>
<pub-id pub-id-type="pmid">26833743</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-18-02056">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panigrahy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wisnowski</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Furtado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lepore</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Paquette</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bluml</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neuroimaging biomarkers of preterm brain injury: Toward developing the preterm connectome</article-title>
<source/>Pediatr. Radiol.
          <year>2012</year>
<volume>42</volume>
<issue>Suppl. 1</issue>
<fpage>S33</fpage>
<lpage>S61</lpage>
<pub-id pub-id-type="doi">10.1007/s00247-011-2239-4</pub-id>
<pub-id pub-id-type="pmid">22395719</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-18-02056">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lofqvist</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Engstrom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sigurdsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hard</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Niklasson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ewald</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Holmström</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Hellström</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit</article-title>
<source/>Pediatrics
          <year>2006</year>
<volume>117</volume>
<fpage>1930</fpage>
<lpage>1938</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2005-1926</pub-id>
<pub-id pub-id-type="pmid">16740833</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-18-02056">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korhonen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Brain derived neurotrophic factor is increased in cerebrospinal fluid of children suffering from asphyxia</article-title>
<source/>Neurosci. Lett.
          <year>1998</year>
<volume>240</volume>
<fpage>151</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(97)00937-3</pub-id>
<pub-id pub-id-type="pmid">9502226</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-18-02056">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Korhonen</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal nerve growth factor—A marker of asphyxia?</article-title>
<source/>Pediatr. Neurol.
          <year>1999</year>
<volume>20</volume>
<fpage>137</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1016/S0887-8994(98)00122-2</pub-id>
<pub-id pub-id-type="pmid">10082343</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-18-02056">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Capovilla</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Connolly</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guilhoto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mathern</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Moshé</surname>
<given-names>S.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology</article-title>
<source/>Epilepsia
          <year>2017</year>
<volume>58</volume>
<fpage>512</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13709</pub-id>
<pub-id pub-id-type="pmid">28276062</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-18-02056">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baram</surname>
<given-names>T.Z.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Snead</surname>
<given-names>O.C.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Horton</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Brain-adrenal axis hormones are altered in the CSF of infants with massive infantile spasms</article-title>
<source/>Neurology
          <year>1992</year>
<volume>42</volume>
<fpage>1171</fpage>
<lpage>1175</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.42.6.1171</pub-id>
<pub-id pub-id-type="pmid">1318521</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-18-02056">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Eghbal-Ahmadi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baram</surname>
<given-names>T.Z.</given-names>
</name>
</person-group>
<article-title>Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression</article-title>
<source/>Ann. Neurol.
          <year>2001</year>
<volume>49</volume>
<fpage>304</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1002/ana.66</pub-id>
<pub-id pub-id-type="pmid">11261504</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-18-02056">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitkänen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Drug-mediated neuroprotection and antiepileptogenesis: Animal data</article-title>
<source/>Neurology
          <year>2002</year>
<volume>59</volume>
<fpage>S27</fpage>
<lpage>S33</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.59.9_suppl_5.S27</pub-id>
<pub-id pub-id-type="pmid">12428029</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-18-02056">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corvin</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Molinos</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Donohoe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Tropea</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor 1 (IGF1) and its active peptide (1-3) IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms</article-title>
<source/>Neurosci. Lett.
          <year>2012</year>
<volume>520</volume>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2012.05.029</pub-id>
<pub-id pub-id-type="pmid">22609570</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-18-02056">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eagles</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Bondy</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>A ketogenic diet increases brain insulin-like growth factor receptor and glucose transporter gene expression</article-title>
<source/>Endocrinology
          <year>2003</year>
<volume>144</volume>
<fpage>2676</fpage>
<lpage>2682</lpage>
<pub-id pub-id-type="doi">10.1210/en.2002-0057</pub-id>
<pub-id pub-id-type="pmid">12746332</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-18-02056">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Monson</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Modulation of glucocorticoid metabolism by the growth hormone—IGF-1 axis</article-title>
<source/>Clin. Endocrinol.
          <year>2007</year>
<volume>66</volume>
<fpage>459</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.02763.x</pub-id>
<pub-id pub-id-type="pmid">17371460</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-18-02056">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Jääskeläinen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Turpeinen</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor-1 is associated with cognitive outcome in infantile spasms</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<fpage>1283</fpage>
<lpage>1289</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02499.x</pub-id>
<pub-id pub-id-type="pmid">20163445</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-18-02056">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szczesny</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Basta-Kaim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Slusarczyk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Trojan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Glombik</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Regulska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leskiewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Budziszewska</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kubera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lason</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>The impact of prenatal stress on insulin-like growth factor-1 and pro-inflammatory cytokine expression in the brains of adult male rats: The possible role of suppressors of cytokine signaling proteins</article-title>
<source/>J. Neuroimmunol.
          <year>2014</year>
<volume>276</volume>
<fpage>37</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.08.001</pub-id>
<pub-id pub-id-type="pmid">25151093</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-18-02056">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rener-Primec</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lozar-Krivec</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Krivec</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Neubauer</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Head growth in infants with infantile spasms may be temporarily reduced</article-title>
<source/>Pediatr. Neurol.
          <year>2006</year>
<volume>35</volume>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2006.03.009</pub-id>
<pub-id pub-id-type="pmid">16939860</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-18-02056">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saemundsen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ludvigsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rafnsson</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Risk of autism spectrum disorders after infantile spasms: A populationbased study nested in a cohort with seizures in the first year of life</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<fpage>1865</fpage>
<lpage>1870</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01688.x</pub-id>
<pub-id pub-id-type="pmid">18557779</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-18-02056">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Boller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ghiasvand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pimentel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Berdichevsky</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Neuroprotective levels of IGF-1 exacerbate epileptogenesis after brain injury</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>32095</fpage>
<pub-id pub-id-type="doi">10.1038/srep32095</pub-id>
<pub-id pub-id-type="pmid">27561791</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-18-02056">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miltiadous</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stamatakis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koutsoudaki</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Tiniakos</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Stylianopoulou</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>IGF-I ameliorates hippocampal neurodegeneration and protects against cognitive deficits in an animal model of temporal lobe epilepsy</article-title>
<source/>Exp. Neurol.
          <year>2011</year>
<volume>231</volume>
<fpage>223</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2011.06.014</pub-id>
<pub-id pub-id-type="pmid">21756906</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-18-02056">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Somer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haltia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lorentz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Norio</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO syndrome)</article-title>
<source/>Clin. Genet.
          <year>1991</year>
<volume>39</volume>
<fpage>287</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.1991.tb03027.x</pub-id>
<pub-id pub-id-type="pmid">2070547</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-18-02056">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Infantile spasms in siblings</article-title>
<source/>J. Pediatr. Neurosci.
          <year>1987</year>
<volume>3</volume>
<fpage>235</fpage>
<lpage>244</lpage>
</element-citation>
</ref>
<ref id="B34-ijms-18-02056">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Somer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Diagnostic criteria and genetics of the PEHO syndrome</article-title>
<source/>J. Med. Genet.
          <year>1993</year>
<volume>30</volume>
<fpage>932</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.30.11.932</pub-id>
<pub-id pub-id-type="pmid">8301648</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-18-02056">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anttonen</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Laari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kousi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Jääskeläinen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Somer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Siintola</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jakkula</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tegelberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lönnqvist</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ZNHIT3 is defective in PEHO syndrome, a severe encephalopathy with cerebellar granule neuron loss</article-title>
<source/>Brain
          <year>2017</year>
<pub-id pub-id-type="doi">10.1093/brain/awx040</pub-id>
<pub-id pub-id-type="pmid">28335020</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-18-02056">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Somer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Turpeinen</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Low insulin-like growth factor (IGF-1) in children with progressive encephalopathy, hypsarrhythmia, and optic atrophy (PEHO) syndrome and cerebellar degeneration</article-title>
<source/>Epilepsia
          <year>1999</year>
<volume>40</volume>
<fpage>1642</fpage>
<lpage>1648</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1999.tb02051.x</pub-id>
<pub-id pub-id-type="pmid">10565594</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-18-02056">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanhatalo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Markedly elevated nitrate/nitrite levels in the cerebrospinal fluid of children with progressive encephalopathy with edema, hypsarrhythmia and optic atrophy and cerebellar degeneration</article-title>
<source/>Epilepsia
          <year>2000</year>
<volume>41</volume>
<fpage>705</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.2000.tb00231.x</pub-id>
<pub-id pub-id-type="pmid">10840402</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-18-02056">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The PEHO syndrome</article-title>
<source/>Brain Dev.
          <year>2001</year>
<volume>23</volume>
<fpage>765</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="doi">10.1016/S0387-7604(01)00283-2</pub-id>
<pub-id pub-id-type="pmid">11701291</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-18-02056">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Low high-density cholesterol in patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome and PEHO-like patients</article-title>
<source/>J. Int. Child Neurol. Assoc.
          <year>2015</year>
<volume>1</volume>
<fpage>1</fpage>
<lpage>4</lpage>
</element-citation>
</ref>
<ref id="B40-ijms-18-02056">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Järvelä</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schleutker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Haataja</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Santavuori</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Puhakka</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Manninen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Palotie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sandkuijl</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Renlund</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Infantile form of neuronal lipofuscinosis (CLN1) maps to the short arm of chromosome 1</article-title>
<source/>Genomics
          <year>1991</year>
<volume>9</volume>
<fpage>170</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1016/0888-7543(91)90235-7</pub-id>
<pub-id pub-id-type="pmid">1672288</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-18-02056">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyynelä</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Henseler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sandhoff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Haltia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Sphingolipid activator proteins (SAPs) are stored together with glycosphingolipids in the infantile neuronal ceroid-lipofuscinosis (INCL)</article-title>
<source/>Am. J. Med. Genet.
          <year>1995</year>
<volume>57</volume>
<fpage>294</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320570236</pub-id>
<pub-id pub-id-type="pmid">7668348</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-18-02056">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedraza</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Salzer</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>The myelin-associated glycoproteins: Membranr disposition, evidence of a novel disulfitide linkage between immunoglobulin-like domains, and posttranslational palmitylation</article-title>
<source/>J. Cell Biol.
          <year>1990</year>
<volume>111</volume>
<fpage>2651</fpage>
<lpage>2661</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.111.6.2651</pub-id>
<pub-id pub-id-type="pmid">1703542</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-18-02056">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanhanen</surname>
<given-names>S.-L.</given-names>
</name>
<name>
<surname>Raininko</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Santavuori</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>MRI evaluation of the brain in infantile ceroid lipofuscinosis. Part 2: MRI findings in 21 patients</article-title>
<source/>J. Child. Neurol.
          <year>1995</year>
<volume>10</volume>
<fpage>445</fpage>
<lpage>550</lpage>
</element-citation>
</ref>
<ref id="B44-ijms-18-02056">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haltia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rapola</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Santavuori</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Infantile type of so-called neuronal ceroid lipofuscinosis. Histological and electron microscopical studies</article-title>
<source/>Acta Neuropathol.
          <year>1973</year>
<volume>26</volume>
<fpage>157</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1007/BF00697751</pub-id>
<pub-id pub-id-type="pmid">4763201</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-18-02056">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vanhanen</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Tyynelä</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Santavuori</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Turpeinen</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>CSF insulin-like growth factor-1 in infantile ceroid lipofuscinosis</article-title>
<source/>Neurology
          <year>2000</year>
<volume>54</volume>
<fpage>1828</fpage>
<lpage>1832</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.54.9.1828</pub-id>
<pub-id pub-id-type="pmid">10802792</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-18-02056">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huhtala</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rytkönen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jalanko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaasalainen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salonen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Närvänen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Native and complexed IGF-1: Biodistribution and pharmacokinetics in infantile neuronal ceroid lipofuscinosis</article-title>
<source/>J. Drug Deliv.
          <year>2012</year>
<pub-id pub-id-type="doi">10.1155/2012/626417</pub-id>
<pub-id pub-id-type="pmid">22778966</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-18-02056">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canitano</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>New experimental treatments for core social domain in autism spectrum disorders</article-title>
<source/>Front. Pediatr.
          <year>2014</year>
<volume>2</volume>
<fpage>61</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2014.00061</pub-id>
<pub-id pub-id-type="pmid">24999471</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-18-02056">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebrahimi-Fakhari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Autism and the synapse: Emerging mechanisms and mechanism-based therapies</article-title>
<source/>Curr. Opin. Neurol.
          <year>2015</year>
<volume>28</volume>
<fpage>91</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1097/WCO.0000000000000186</pub-id>
<pub-id pub-id-type="pmid">25695134</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-18-02056">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voineagu</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Blencowe</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Transcriptomic analysis of autistic brain reveals convergant molecular pathology</article-title>
<source/>Nature
          <year>2011</year>
<volume>474</volume>
<fpage>380</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.1038/nature10110</pub-id>
<pub-id pub-id-type="pmid">21614001</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-18-02056">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebert</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Activity-dependent neuronal signaling and autism spectrum disorder</article-title>
<source/>Nature
          <year>2013</year>
<volume>493</volume>
<fpage>327</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1038/nature11860</pub-id>
<pub-id pub-id-type="pmid">23325215</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-18-02056">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanhala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Turpeinen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2001</year>
<volume>43</volume>
<fpage>614</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162201001116</pub-id>
<pub-id pub-id-type="pmid">11570630</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-18-02056">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Makkonen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vanhala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Turpeinen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kuikka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kokki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid growth actors IGF-1 and IGF-2 in infantile autism</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2006</year>
<volume>48</volume>
<fpage>751</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162206001605</pub-id>
<pub-id pub-id-type="pmid">16904022</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-18-02056">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ingram.</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tisdale</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Embryological origin for autism; developmental anomalies of the cranial nerve motor nuclei</article-title>
<source/>J. Comp. Neurol.
          <year>1996</year>
<volume>370</volume>
<fpage>247</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19960624)370:2&lt;247::AID-CNE8&gt;3.0.CO;2-2</pub-id>
<pub-id pub-id-type="pmid">8808733</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-18-02056">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neurobiology of autism</article-title>
<source/>Ann. Neurol.
          <year>1998</year>
<volume>43</volume>
<fpage>7</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410430106</pub-id>
<pub-id pub-id-type="pmid">9450763</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-18-02056">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Histoanatomic observations in the brain in early infantile autism</article-title>
<source/>Neurology
          <year>1985</year>
<volume>35</volume>
<fpage>866</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.35.6.866</pub-id>
<pub-id pub-id-type="pmid">4000488</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-18-02056">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casanova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buxhoeveden</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Switala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Minicolumnar pathology in autism</article-title>
<source/>Neurology
          <year>2002</year>
<volume>58</volume>
<fpage>428</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.58.3.428</pub-id>
<pub-id pub-id-type="pmid">11839843</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-18-02056">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Brain overgrowth in autism during a critical time in developmental implications for frontal pyramidal neuron and interneuron development and connectivity</article-title>
<source/>Int. J. Dev. Neurosci.
          <year>2005</year>
<volume>23</volume>
<fpage>153</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijdevneu.2005.01.003</pub-id>
<pub-id pub-id-type="pmid">15749242</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-18-02056">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redcay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>When is the brain enlarged in autism? A meta-analysis of all brain size reports</article-title>
<source/>Biol. Psychiatry
          <year>2005</year>
<volume>58</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.03.026</pub-id>
<pub-id pub-id-type="pmid">15935993</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-18-02056">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piven</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saliba</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arndt</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>An MRI study of autism. The cerebellum revisted</article-title>
<source/>Neurology
          <year>1997</year>
<volume>49</volume>
<fpage>44546</fpage>
<lpage>44551</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.49.2.546</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-18-02056">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nascimbene</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Neurogial activation and neuroinflammation in the brain of patients with autism</article-title>
<source/>Ann. Neurol.
          <year>2005</year>
<volume>57</volume>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20315</pub-id>
<pub-id pub-id-type="pmid">15546155</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-18-02056">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sparks</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aylward</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Echelard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arthru</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marvilla</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Giedd</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Munson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain structural abnormalities in young children with autism spectrum disorder</article-title>
<source/>Neurology
          <year>2012</year>
<volume>59</volume>
<fpage>184</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.59.2.184</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-18-02056">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Markris</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Filipek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Normandin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Caviness</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Localization of white matter increase in autism and developmental language disorder</article-title>
<source/>Ann. Neurol.
          <year>2004</year>
<volume>55</volume>
<fpage>530</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20032</pub-id>
<pub-id pub-id-type="pmid">15048892</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-18-02056">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davincovitch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gartside</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Head circumfrence measurements in children with autism</article-title>
<source/>J. Child. Neurol.
          <year>1996</year>
<volume>11</volume>
<fpage>389</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="doi">10.1177/088307389601100509</pub-id>
<pub-id pub-id-type="pmid">8877607</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-18-02056">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Nordahl</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Wootton-Gorges</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liston</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Ozonoff</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Early brain enlargement and elevated extra-axial fluid in infants who develop autism spectrum disorder</article-title>
<source/>Brain
          <year>2013</year>
<volume>136</volume>
<fpage>2825</fpage>
<lpage>2835</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awt166</pub-id>
<pub-id pub-id-type="pmid">23838695</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-18-02056">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazlett</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Munsell</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Styner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Elison</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Botteron</surname>
<given-names>K.N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early brain development in infants at high risk for autism spectrum disorder</article-title>
<source/>Nature
          <year>2017</year>
<volume>542</volume>
<fpage>348</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1038/nature21369</pub-id>
<pub-id pub-id-type="pmid">28202961</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-18-02056">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazlett</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gerig</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Styner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vachet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Piven</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Early brain overgrowth in autism associated with an increase in cortical surface area before age of 2</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2012</year>
<volume>68</volume>
<fpage>467</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.39</pub-id>
<pub-id pub-id-type="pmid">21536976</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-18-02056">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grether</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Groen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dambrosia</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Dickens</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Jelliffe</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Neuropeptides and neurotrophins in neonatal fluid of children with autism and mental retardation</article-title>
<source/>Ann. Neurol.
          <year>2001</year>
<volume>49</volume>
<fpage>597</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1002/ana.1024</pub-id>
<pub-id pub-id-type="pmid">11357950</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-18-02056">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Greene-Colozzi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sadowski</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Leech</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Regehr</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice</article-title>
<source/>Nature
          <year>2012</year>
<volume>488</volume>
<fpage>647</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1038/nature11310</pub-id>
<pub-id pub-id-type="pmid">22763451</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-18-02056">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reith</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hashmi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Gambello</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex</article-title>
<source/>Neurobiol. Dis.
          <year>2013</year>
<volume>51</volume>
<fpage>93</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2012.10.014</pub-id>
<pub-id pub-id-type="pmid">23123587</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-18-02056">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres-Aleman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Villaba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nieto-Bona</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor-1 modulation of cerebellar cell populations is developmentally stage-dependent and mediated by specific intracellular pathways</article-title>
<source/>Neuroscience
          <year>1998</year>
<volume>83</volume>
<fpage>321</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4522(97)00367-9</pub-id>
<pub-id pub-id-type="pmid">9460743</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-18-02056">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres-Aleman</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor-1 and central neurodegenerative diseases</article-title>
<source/>Endocrinol. Metab. Clin. N. Am.
          <year>2012</year>
<volume>41</volume>
<fpage>395</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1016/j.ecl.2012.04.016</pub-id>
<pub-id pub-id-type="pmid">22682637</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-18-02056">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Townsend</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Covington</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Westerfield</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Lyden</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Press</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Spatial attention deficits in patients with acquired or developmental cerebellar abnormality</article-title>
<source/>J. Neurosci.
          <year>1999</year>
<volume>19</volume>
<fpage>5632</fpage>
<lpage>5643</lpage>
<pub-id pub-id-type="pmid">10377369</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-18-02056">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Cerebellar function in autism: Functional magnetic resonance image activation during a simple motor task</article-title>
<source/>Biol. Psychiatry
          <year>2004</year>
<volume>56</volume>
<fpage>269</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.06.005</pub-id>
<pub-id pub-id-type="pmid">15312815</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-18-02056">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adrien</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Rossignol-Deletang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martineau</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Couturier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Barthelemy</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Regulation of cognitive activity and early communication development in young autistic, mentally retarded, and young normal children</article-title>
<source/>Dev. Psychobiol.
          <year>2001</year>
<volume>39</volume>
<fpage>124</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1002/dev.1036</pub-id>
<pub-id pub-id-type="pmid">11568882</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-18-02056">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Limperopoulos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bassan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gauvreau</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>R.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sullivan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Avery</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soul</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ringer</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Does Cerebellar Injury in Premature Infants Contribute to the High Prevalence of Long-term Cognitive, Learning, and Behavioral Disability in Survivors?</article-title>
<source/>Pediatrics
          <year>2007</year>
<volume>120</volume>
<fpage>584</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2007-1041</pub-id>
<pub-id pub-id-type="pmid">17766532</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-18-02056">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hediger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Molley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chrousos</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Manning-Courtney</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Brasington</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>England</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>Elevated levels of growth related hormones in autism and autism spectrum disorder</article-title>
<source/>Clin. Endocrinol.
          <year>2007</year>
<volume>67</volume>
<fpage>230</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.02868.x</pub-id>
<pub-id pub-id-type="pmid">17547689</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-18-02056">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Treatment of autistic spectrum disorder with insulin-like growth factors</article-title>
<source/>Eur. J. Paediatr. Neurol.
          <year>2016</year>
<volume>20</volume>
<fpage>816</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2016.08.005</pub-id>
<pub-id pub-id-type="pmid">27562096</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-18-02056">
<label>78.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Blue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moloney</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hohmann</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Serotonin dysfunction in autism</article-title>
<source/>Autism Current Theories and Evidence
          <person-group person-group-type="editor">
<name>
<surname>Zimmerman</surname>
<given-names>A.</given-names>
</name>
</person-group>
<publisher-name>Humana Press</publisher-name>
<publisher-loc>Totova, NJ, USA</publisher-loc>
<year>2008</year>
<fpage>111</fpage>
<lpage>182</lpage>
</element-citation>
</ref>
<ref id="B79-ijms-18-02056">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Muzik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Behen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rothermel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Janisse</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>H.T.</given-names>
</name>
</person-group>
<article-title>Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children</article-title>
<source/>Ann. Neurol.
          <year>1999</year>
<volume>45</volume>
<fpage>287</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1002/1531-8249(199903)45:3&lt;287::AID-ANA3&gt;3.0.CO;2-9</pub-id>
<pub-id pub-id-type="pmid">10072042</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-18-02056">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Muzik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Rothermel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Molley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Behen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Magner</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>de Silva</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>H.T.</given-names>
</name>
</person-group>
<article-title>Altered serotonin synthesis in denththalamic pathway in autistic boys</article-title>
<source/>Ann. Neurol.
          <year>1997</year>
<volume>42</volume>
<fpage>66</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410420420</pub-id>
<pub-id pub-id-type="pmid">9382481</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-18-02056">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castren</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neurotrophic effects of antidepressant drugs</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2004</year>
<volume>4</volume>
<fpage>58</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2003.10.004</pub-id>
<pub-id pub-id-type="pmid">15018840</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-18-02056">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makkonen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kuikka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kokki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bressler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism</article-title>
<source/>J. Pediatr. Neurol.
          <year>2011</year>
<volume>9</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">29056860</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-18-02056">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schilling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Heuser</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Paslakis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wudy</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Deuschle</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Treatment with antidepressants increases insulin-like growth factor-1 in cerebrospinal fluid</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2011</year>
<volume>31</volume>
<fpage>390</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e3182189d86</pub-id>
<pub-id pub-id-type="pmid">21532371</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-18-02056">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaplin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zagurski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Novotny</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wasserman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iyengar</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A placebo-controlled crossover trial of liquid fluoxetine on repetative behaviors in childhood and adolescent autism</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<fpage>582</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300627</pub-id>
<pub-id pub-id-type="pmid">15602505</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-18-02056">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makkonen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kokki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Airaksinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kuikka</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Serotonin and dopamine transporter binding in children and adolescents with autism</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2008</year>
<volume>50</volume>
<fpage>593</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2008.03027.x</pub-id>
<pub-id pub-id-type="pmid">18754896</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-18-02056">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anlar</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Oktem</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bakkaloglu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haliloglu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oguz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Unal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pehlivanturk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gokler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ozbesler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yordam</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Urinary epidermal and insulin-like growth factor excretion in autistic children</article-title>
<source/>Neuropediatrics
          <year>2007</year>
<volume>38</volume>
<fpage>151</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-990282</pub-id>
<pub-id pub-id-type="pmid">17985266</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-18-02056">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>O.H.</given-names>
</name>
<name>
<surname>Pevsner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Naidu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neurobiology of Rett syndrome: A genetic disorder of synapse development</article-title>
<source/>Brain Dev.
          <year>2001</year>
<volume>23</volume>
<issue>Suppl. 1</issue>
<fpage>S206</fpage>
<lpage>S213</lpage>
<pub-id pub-id-type="doi">10.1016/S0387-7604(01)00351-5</pub-id>
<pub-id pub-id-type="pmid">11738874</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-18-02056">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Naidu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Recent advances in understanding synaptic abnormalities in Rett syndrome</article-title>
<source/>F1000Research
          <year>2015</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.12688/f1000research.6987.1</pub-id>
<pub-id pub-id-type="pmid">26918155</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-18-02056">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The neuropathology of Rett syndrome-overview 1994</article-title>
<source/>Neuropediatrics
          <year>1995</year>
<volume>26</volume>
<fpage>100</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-979736</pub-id>
<pub-id pub-id-type="pmid">7566445</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-18-02056">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenk</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hauss-Wegryniak</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Altered cholinergic function in the basal forebrain of girls with Rett syndrome</article-title>
<source/>Neuropediatrics
          <year>1999</year>
<volume>30</volume>
<fpage>125</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-973476</pub-id>
<pub-id pub-id-type="pmid">10480206</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-18-02056">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cook</surname>
<given-names>E.H.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Courchesne</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haas.</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Leventhal</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Evidence of linkage between the serotonin transporter and autistic disorder</article-title>
<source/>Mol. Psychiatry
          <year>1997</year>
<volume>2</volume>
<fpage>247</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">9152989</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-18-02056">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raymond</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bauman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Hippocampus in autism: A golgi analysis</article-title>
<source/>Acta Neuropatol.
          <year>1996</year>
<volume>91</volume>
<fpage>117</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1007/s004010050401</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-18-02056">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiss</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Faruque</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Naidu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beauty</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Neuroanatomy of Rett syndrome: A volumetric imaging study</article-title>
<source/>Ann. Neurol.
          <year>1993</year>
<volume>34</volume>
<fpage>227</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410340220</pub-id>
<pub-id pub-id-type="pmid">8338347</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-18-02056">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipani</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Bhattacharjee</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Corey</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Reduced nerve growth factor in Rett syndrome postmortem brain tissue</article-title>
<source/>Neuropathol. Exp. Neurol.
          <year>2000</year>
<volume>59</volume>
<fpage>889</fpage>
<lpage>895</lpage>
<pub-id pub-id-type="doi">10.1093/jnen/59.10.889</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-18-02056">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lappalainen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liewendahl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sainio</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Brain perfusion SPECT and EEG findings in Rett syndrome</article-title>
<source/>Acta Neurol. Scand.
          <year>1997</year>
<volume>95</volume>
<fpage>44</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0404.1997.tb00067.x</pub-id>
<pub-id pub-id-type="pmid">9048985</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-18-02056">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lappalainen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Low levels of nerve growth factor in cerebrospinal fluid of patients with Rett syndrome</article-title>
<source/>J. Child. Neurol.
          <year>1996</year>
<volume>11</volume>
<fpage>296</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1177/088307389601100407</pub-id>
<pub-id pub-id-type="pmid">8807419</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-18-02056">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vanhala</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Levels of cerebrospinal fluid nerve-growth factor differ in infantile autism and Rett syndrome</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2000</year>
<volume>15</volume>
<fpage>797</fpage>
<lpage>802</lpage>
</element-citation>
</ref>
<ref id="B98-ijms-18-02056">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yuksel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gökkurt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Oguz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Anlar</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Increased insulin-like growth factor-1 in cerebrospinal fluid of advanced subacute sclerosing panencephalitis patients</article-title>
<source/>Eur. J. Paediatr. Neurol.
          <year>2016</year>
<volume>20</volume>
<fpage>611</fpage>
<lpage>615</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2016.03.007</pub-id>
<pub-id pub-id-type="pmid">27061773</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-18-02056">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Madathi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sama</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Goo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saatman</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Conditional Overexpression of Insulin-Like Growth Factor-1 Enhances Hippocampal Neurogenesis and Restores Immature Neuron Dendritic Processes after Traumatic Brain Injury</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>2014</year>
<volume>73</volume>
<fpage>734</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0000000000000092</pub-id>
<pub-id pub-id-type="pmid">25003234</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-18-02056">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozdagi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Tavassoli</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay</article-title>
<source/>Mol. Autism
          <year>2013</year>
<volume>4</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-9</pub-id>
<pub-id pub-id-type="pmid">23621888</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-18-02056">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tropea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Giacometti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McCurry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Flannery</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sur</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Partial reversal of Rett syndrome-like symptoms in MECP2 mutant mice</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>2029</fpage>
<lpage>2034</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0812394106</pub-id>
<pub-id pub-id-type="pmid">19208815</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-18-02056">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>IGF-1 allevates NMDA-induced excitotocity in cultured hippocampal neurons against autophagy via NR2B/Pi3K-AKT-mTOR pathway</article-title>
<source/>J. Cell Physiol.
          <year>2014</year>
<volume>229</volume>
<fpage>1618</fpage>
<lpage>1629</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.24607</pub-id>
<pub-id pub-id-type="pmid">24604717</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-18-02056">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchetto</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Belinson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vandodaria</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Beltrao-Braga</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Trujillo</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>A.P.D.</given-names>
</name>
<name>
<surname>Padmannabhan</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered proliferation and networks in neural cells derived from idiopathic autistic individuals</article-title>
<source/>Mol. Psychiatry
          <year>2017</year>
<volume>22</volume>
<fpage>820</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.95</pub-id>
<pub-id pub-id-type="pmid">27378147</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-18-02056">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khwaja</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>O’Leary</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Finkelstein</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>C.A.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Vogel-Farley</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>DeGregorio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>I.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for treatment of Rett syndrome</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>25</volume>
<fpage>4596</fpage>
<lpage>4601</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1311141111</pub-id>
<pub-id pub-id-type="pmid">24623853</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-18-02056">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krady</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liberto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kremlev</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Levison</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Ciliary neurotrophic factor and interleukin-6 differently activate microglia</article-title>
<source/>J. Neurosci. Res.
          <year>2008</year>
<volume>86</volume>
<fpage>1538</fpage>
<lpage>1547</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.21620</pub-id>
<pub-id pub-id-type="pmid">18214991</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-18-02056">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S.-E.</given-names>
</name>
<name>
<surname>Dantzer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McCusker</surname>
<given-names>R.H.</given-names>
</name>
</person-group>
<article-title>Central administration of insulin-like growth factor-1 decreases depressive-like behavior and brain cytokine expression in mice</article-title>
<source/>J. Neuroinflamm.
          <year>2010</year>
<volume>8</volume>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-12</pub-id>
<pub-id pub-id-type="pmid">21306618</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-18-02056">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders</article-title>
<source/>Int. J. Dev. Neurosci.
          <year>2014</year>
<volume>35</volume>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijdevneu.2014.03.006</pub-id>
<pub-id pub-id-type="pmid">24662006</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-18-02056">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Betancur</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boeckers</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Bockmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chaste</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fauchereau</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nygren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rastam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Anckarsäter</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders</article-title>
<source/>Nat. Genet.
          <year>2007</year>
<volume>39</volume>
<fpage>25</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1038/ng1933</pub-id>
<pub-id pub-id-type="pmid">17173049</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-18-02056">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolevzon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grodberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tavassoli</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chaplin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Soorya</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A pilot controlled trial ofinsulin-like growth factor-1 in children with Phelan-McDermid syndrome</article-title>
<source/>Mol. Autism
          <year>2014</year>
<volume>5</volume>
<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-54</pub-id>
<pub-id pub-id-type="pmid">25685306</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-18-02056">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shcheglovitov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schleglotiva</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Portmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sebastiano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Krawisz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Froehlich</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>J.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome</article-title>
<source/>Nature
          <year>2013</year>
<volume>503</volume>
<fpage>267</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1038/nature12618</pub-id>
<pub-id pub-id-type="pmid">24132240</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-18-02056">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Microglia: The constant gardeners</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>570</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1038/485570a</pub-id>
<pub-id pub-id-type="pmid">22660301</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-18-02056">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chernausek</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Backeljauw</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Frane</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kuntze</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Underwood</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. GH Insensitivity Syndrome Collaborative Group et al</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2007</year>
<volume>92</volume>
<fpage>902</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2006-1610</pub-id>
<pub-id pub-id-type="pmid">17192294</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-18-02056">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guevara-Arguire</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Balasubramanian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Guevara-Aguire</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Madia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martin-Montalvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saavedra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ingles</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Growth hormone receptor deficiency is associated with a major reduction in pro-aging, cancer, and diabetes in humans</article-title>
<source/>Sci. Transl. Med.
          <year>2011</year>
<volume>3</volume>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3001845</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-18-02056">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fintini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brufani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cappa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency</article-title>
<source/>Ther. Clin. Risk Manag.
          <year>2009</year>
<volume>5</volume>
<fpage>553</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="pmid">19707272</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-18-02056">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laron</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Lessons from 50 years of study of Laron syndrome</article-title>
<source/>Endocrinol. Pract.
          <year>2015</year>
<volume>21</volume>
<fpage>1395</fpage>
<lpage>1402</lpage>
<pub-id pub-id-type="doi">10.4158/EP15939.RA</pub-id>
<pub-id pub-id-type="pmid">26401581</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-18-02056">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurtzhals</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schäffer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jonassen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trüb</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Correlations of receptor binding and mitogenic potencies of insulin analogs designed for clinical use</article-title>
<source/>Diabetes
          <year>2000</year>
<volume>49</volume>
<fpage>999</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="doi">10.2337/diabetes.49.6.999</pub-id>
<pub-id pub-id-type="pmid">10866053</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-18-02056">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Scusa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Congiu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Congiu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benincasa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morescalchi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bottiglioni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Di Marco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Borelli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bonuccelli</surname>
<given-names>U.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IGF1 as a potential treatment for Rett syndrome; safety assessment in six Rett patients</article-title>
<source/>Autism Res. Treat.
          <year>2012</year>
<volume>2012</volume>
<fpage>679801</fpage>
<pub-id pub-id-type="doi">10.1155/2012/679801</pub-id>
<pub-id pub-id-type="pmid">22934177</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-18-02056">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scusa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Benincasa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bottiglioni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Congiu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vadhatpour</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Romanelli</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Gemo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Puccetti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Repeated insulin-like growth factor 1 treatment in a patient with Rett syndrome: A single case study</article-title>
<source/>Front. Pediatr.
          <year>2014</year>
<volume>2</volume>
<fpage>52</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2014.00052</pub-id>
<pub-id pub-id-type="pmid">24918098</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-18-02056">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walton</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Dunshea</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>In Vivo actions of IGF analogues with poor affinities for IGFBPs: Metabolic and growth effects in pigs of different ages and GH responsiveness</article-title>
<source/>Prog. Growth Factor Res.
          <year>1995</year>
<volume>6</volume>
<fpage>385</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1016/0955-2235(95)00007-0</pub-id>
<pub-id pub-id-type="pmid">8817682</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-18-02056">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Banarjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Petravicz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Woodson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mellios</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tropea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sur</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome</article-title>
<source/>Proc Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>9941</fpage>
<lpage>9946</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1311685111</pub-id>
<pub-id pub-id-type="pmid">24958891</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-18-02056">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGraw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Samaco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Adult function requires MeCP2</article-title>
<source/>Science
          <year>2011</year>
<volume>333</volume>
<fpage>186</fpage>
<pub-id pub-id-type="doi">10.1126/science.1206593</pub-id>
<pub-id pub-id-type="pmid">21636743</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-18-02056">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollack</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schernhammer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hankinson</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factors in neoplasia</article-title>
<source/>Nat. Rev. Cancer
          <year>2004</year>
<volume>4</volume>
<fpage>505</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="doi">10.1038/nrc1387</pub-id>
<pub-id pub-id-type="pmid">15229476</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-18-02056">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pinzi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bourhis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Mechanisms of Disease: Signaling of the insulin-like growth factor 1 receptor pathway therapeutic perspectives in cancer</article-title>
<source/>Nat. Clin. Pract. Oncol.
          <year>2007</year>
<volume>4</volume>
<fpage>591</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1038/ncponc0934</pub-id>
<pub-id pub-id-type="pmid">17898809</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-18-02056">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Somma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pivonello</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grasso</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Savastano</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: An observational, exploratory study in 404 subjects</article-title>
<source/>Eur. J. Endocrinol.
          <year>2008</year>
<volume>159</volume>
<fpage>389</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1530/EJE-08-0201</pub-id>
<pub-id pub-id-type="pmid">18603571</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-18-02056">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callagher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>LeRoith</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Is grow hormone resistance/IGF-1 reduction good for you?</article-title>
<source/>Cell Metab.
          <year>2011</year>
<volume>13</volume>
<fpage>355</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2011.03.003</pub-id>
<pub-id pub-id-type="pmid">21459318</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-18-02056">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dattani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>How to use insulin-like factor 1 (IGF1)</article-title>
<source/>Arch. Dis. Child Educ. Pract. Ed.
          <year>2012</year>
<volume>97</volume>
<fpage>144</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1136/archdischild-2011-300265</pub-id>
<pub-id pub-id-type="pmid">22267103</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-18-02056">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pozzo-Miller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pati</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Rett syndrome: Reaching for clinical trials</article-title>
<source/>Neurotherapeutics
          <year>2015</year>
<volume>12</volume>
<fpage>631</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-015-0353-y</pub-id>
<pub-id pub-id-type="pmid">25861995</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>